Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mimeixin versus oxycodone sustained-release tablets for opioid-induced constipation in moderate to severe cancer pain
ChiCTR2500096797Phase 4Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of oxycodone + naloxone and oxycodone in cancer pain and opioid-induced constipation (OIC) (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Improvement in bowel function. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
oxycodone + naloxoneoxycodone
03
Conditions
cancer painopioid-induced constipation (OIC)
Beyond the preview
Go deeper on ChiCTR2500096797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096797.